Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday

Ascendis Pharma A/S (NASDAQ:ASND) is expected to post its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect Ascendis Pharma A/S to post earnings of ($1.31) per share and revenue of $117.02 million for the quarter.

Ascendis Pharma A/S Stock Performance

ASND opened at $129.37 on Wednesday. The stock has a market capitalization of $7.85 billion, a P/E ratio of -16.01 and a beta of 0.65. The company’s 50-day simple moving average is $133.46 and its two-hundred day simple moving average is $133.07. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. TD Cowen lowered their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Stifel Nicolaus increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $192.07.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.